A New Era in Alzheimer’s Disease Diagnosis: The Promise of Blood-Based Biomarkers for Better Management and Treatment
Main Article Content
Abstract
September is World Alzheimer’s Month, various awareness activities are organized throughout the globe. Alzheimer’s disease (AD), the most common cause of dementia, represents one of the greatest challenges to healthy ageing and public health. Its progressive deterioration of memory, cognition, behaviour, and functional independence places a considerable burden on patients, families, caregivers, and healthcare systems. Although research has advanced our understanding of the disease, delayed diagnosis remains a major obstacle to timely intervention1. The emergence of blood-based biomarkers for Alzheimer’s disease therefore represents a significant milestone in modern neuroscience and clinical practice.
References
Teunissen CE, Verberk IMW, Thijssen EH, Vermenlen M, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. Lancet Neurol. 2022;21(1):66-77.
Alzheimer’s Association. Appropriate use recommendations for blood-based biomarkers in Alzheimer’s disease. Alzheimer’s Dement. 2025.
US Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer’s disease [Internet]. Silver Spring (MD): FDA; 2025 May 16 [cited 2026 Sep 15].
Ayalew BD, et al. FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio for Alzheimer’s disease assessment. JClin Med. 2025.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9-21.
Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s Dement. 2011;7(4):367-385. Cummings J, Lee G, Nahed P, Kinnunen K, Watling M, Trenchard L, et al. Alzheimer’s disease drug development pipeline: 2024. Alzheimer’s Dement (N Y). 2024;10(2):e12465.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.